CIU and XOLAIR Frequently Asked Questions
Search below for answers to questions regarding CIU and XOLAIR.
For 7 out of 10 people with chronic hives, doctors cannot find a
When this happens, the diagnosis is CIU.
CIU stands for Chronic Idiopathic Urticaria. Chronic means lasting 6
or more. Idiopathic means that the cause is unknown. Urticaria is the medical name for hives.
XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat adults and children 12 years of age and older with chronic idiopathic urticaria (CIU; chronic hives without a known cause) who continue to have hives that are not controlled by H1 antihistamine treatment. XOLAIR is not used to treat other forms of urticaria.
Learn how XOLAIR may help
XOLAIR is given by an injection just under the skin (subcutaneous injection) every 4 weeks. This should be done by your healthcare provider, in a healthcare setting.
- You will get 1 or more injections per visit, depending on the dose your doctor has prescribed
- Each injection takes about 5-10 seconds to administer
- Your healthcare provider will monitor you closely during each injection and for a period of time after your injection(s). He or she will be looking for symptoms of a severe, life-threatening allergic reaction called “anaphylaxis” [an-uh-fuh-lak-sis]
- You may not see improvement in your symptoms right after XOLAIR treatment
- Do not decrease or stop taking any of your other medicines unless your healthcare providers tell you to.
In two clinical studies XOLAIR helped reduce the severity of itch and number of hives in study participants who continued to have symptoms that were not controlled by antihistamines. Your results may vary. View the full XOLAIR CIU clinical study results to learn more.
You should not decrease or stop taking any of your other hive medicine unless your specialist tells you to. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.
Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:
- wheezing, shortness of breath, cough, chest tightness, or trouble breathing
- low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom"
- flushing, itching, hives, or feeling warm
- swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing
Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after your injection. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction after leaving the healthcare provider's office or treatment center.
Do not receive XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR.
Click here for more Important Safety Information regarding XOLAIR.
The most common side effects of XOLAIR:
- In people with chronic idiopathic urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection.
These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682.
Please see full Prescribing Information, including Medication
Guide for additional Important Safety Information.
A number of programs, including the XOLAIR Co-pay Program* have been created to help people who qualify to pay for XOLAIR and the cost of getting the injection.
Read more about XOLAIR financial assistance options
*In order to be eligible for the XOLAIR Co-pay Program, the patient must confirm that they meet the eligibility criteria and agree to the rules set forth in the terms and conditions.